Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CDT EquityCDT -11.76%11 Equity-to-Asset is 0.83 as of Mar. 2026. GuruFocus rates CDT with a GF Score™ of 11/100. The stock has 5 warning signs investors should review. Among 1,415 Biotechnology companies, CDT Equity ranks better than 70.81% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CDT Equity's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $105.45 Mil. CDT Equity's Total Assets for the quarter that ended in Mar. 2026 was $127.09 Mil.
The historical rank and industry rank for CDT Equity's Equity-to-Asset or its related term are showing as below:
CDT'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2017.8 Med: -0.63 Max: 0.83
Current: 0.83
During the past 5 years, the highest Equity to Asset Ratio of CDT Equity was 0.83. The lowest was -2017.80. And the median was -0.63.
CDT's Equity-to-Asset is ranked better than 70.81% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs CDT: 0.83
CDT Equity (NAS:CDT) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CDT Equity Equity-to-Asset Related Terms
CDT Equity Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for CDT Equity's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CDT vs BBLG, CLDI, BPTH: Equity-to-Asset Comparison
For the Biotechnology subindustry, CDT Equity's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CDT Equity Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CDT Equity's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CDT Equity's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CDT Equity's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CDT Equity (CDT) has a Equity-to-Asset of 0.83 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CDT Equity and its competitors. According to the industry distribution chart, CDT Equity ranks #413 out of 1415 companies in the Biotechnology industry, placing it in the top 29.2%.
Is CDT Equity's Equity-to-Asset too high?
CDT Equity's current Equity-to-Asset is 0.83. The Biotechnology industry median Equity-to-Asset is 0.68. CDT Equity's value of 0.83 is 22.1% above this industry median. Based on the distribution chart, CDT Equity ranks #413 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CDT Equity has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's Equity-to-Asset compare to BBLG and CLDI?
According to the Biotechnology industry distribution chart, CDT Equity ranks #413 out of 1415 companies for Equity-to-Asset. This puts CDT Equity in the upper half of its industry. The industry median Equity-to-Asset is 0.68. CDT Equity's value of 0.83 is 22.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CDT Equity's current Equity-to-Asset of 0.83 is 22.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CDT Equity and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CDT Equity's current Equity-to-Asset is 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current Equity-to-Asset of 0.83. The current Equity-to-Asset is 0.83 and 22.1% above the Biotechnology industry median of 0.68. CDT Equity's overall GF Score™ is 11/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CDT Equity (CDT), the current Equity-to-Asset is 0.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
11GF Score
Get the complete analysis for CDT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDT has been successfully added to your 
